Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Taking a high-stakes product liability case to trial for a major pharmaceutical company is nerve-racking enough. Try doing it with criminal charges hanging over your head. In May, prominent Los Angeles litigator Pierce O’Donnell of O’Donnell & Shaeffer was defending Pfizer Inc. in a case brought on behalf of two people who died after taking the diabetes drug Rezulin and a third who became ill. Rezulin was taken off the market in 2000 after it was linked to liver failure and 63 deaths. (More than 35,000 individuals have sued Pfizer over the drug, and the company has a mixed record with the handful that have gone to trial.) In this first Rezulin trial in California, O’Donnell was facing off against plaintiffs heavyweight Thomas Girardi of Los Angeles’ Girardi & Keese. On May 20, six weeks into the trial, the Los Angeles County district attorney’s office filed a misdemeanor complaint against O’Donnell, accusing him of making illegal campaign contributions to Los Angeles Mayor James Hahn in 2000 and 2001. The 26-count complaint accuses O’Donnell and seven others of “laundering” contributions by sending $25,000 in the names of others, allowing them to skirt limits of $1,000 per donor. O’Donnell could face six months behind bars for each count, if convicted. O’Donnell’s attorney, George O’Connell of Sacramento’s Stevens & O’Connell, persuaded the court to keep the complaint under seal until the Rezulin trial ended. O’Donnell claims the threat of prison time didn’t distract him during the trial. “It probably made me focus more,” he says. On May 27, after two days of deliberations, the state court jury returned a defense verdict, finding that Girardi had failed to show that Rezulin was a substantial factor in the plaintiffs’ deaths and illness. Pfizer was “very pleased” with the verdict, according to a company spokesman. As for the criminal matter, O’Donnell notes that he has “an unblemished record” and “fully expect[s] a favorable resolution.” Susan Beck is a San Francisco-based senior writer for The American Lawyer magazine, a Recorder affiliate based in New York City. Her e-mail address is sbeck @ amlaw.com.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.